Avidity
Amy Halseth is an experienced healthcare professional specializing in clinical development and medical sciences. At Avidity Biosciences, Inc., Amy serves as Executive Director of Clinical Development, while previously holding the position of Executive Director of Clinical Science at Samumed, LLC. Amy's extensive background includes leadership roles such as Vice President of Medical Sciences at Neurana Pharmaceuticals and Vice President of Global Development at Nalpropion Pharmaceuticals, Inc. Additionally, Amy has experience at Orexigen Therapeutics, where responsibilities included Director of Clinical Development and Medical Affairs.
This person is not in any teams
This person is not in any offices
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.